[Solved] Solving a psilocybin trip headache with ibuprofen

There are no known direct pharmacological interactions a comparison between psilocybin (from truffles/magic mushrooms) and NSAIDs (ibuprofen, naproxen, diclofenac) has been described. Psilocybin is primarily activated via serotonin receptors and metabolized via dephosphorylation and UGT/MAO, whereas NSAIDs inhibit COX enzymes. In the literature, no notification dangerous interactions have been found. However, it is true that NSAIDs carry their own risks to the kidneys, liver, and cardiovascular system, independent of psilocybin. Psilocybin itself only causes temporarily increased blood pressure and heart rate and is normally harmless to the liver/kidney. After a trip, headaches or muscle pain can be treated with NSAIDs or paracetamol – this is safe and common practice, as recommended in trials. Serious side effects or harm from the combination have not been reported. However, there is limited clinical research; a few case reports primarily confirm safety and pain reduction after psilocybin use.

Pharmacological interactions

Psilocybin acts primarily as a 5-HT₂A agonist; it is not metabolized via the CYP system but is converted into psilocin (via phosphatases, UGT, MAO). NSAIDs inhibit cyclooxygenase (COX-1/2) and affect prostaglandins. The mechanisms of action do not overlap, so there is no pharmacodynamic interaction (NSAIDs do not enhance or inhibit the psychedelic effect). Furthermore, there are no known pharmacokinetic interactions: NSAIDs and psilocybin use different metabolic pathways. A recent review found no signs of adverse combinations with anti-inflammatory drugs. On the contrary, in psilocybin studies, NSAIDs (such as ibuprofen or aspirin) are routinely permitted to combat headaches afterwards, without problems. In summary: no reported contraindication for concomitant use, provided that underlying organ disorders are ruled out and at a normal dosage.

Risks to organs

Kidneys

NSAIDs can reduce renal blood flow through prostaglandin inhibition, particularly in cases of dehydration or high doses. This can lead to acute renal failure. Symptoms sometimes appear after only 1–3 days. Psilocybin rarely causes direct kidney damage; only one case of acute renal failure following Psilocybe cubensis use has been described. This was exceptional; under most circumstances, psilocybin is renally harmless. Combination: In theory, dehydration caused by psychedelics can increase the renal risk associated with NSAIDs. To prevent this, adequate fluid intake is important. With healthy use of NSAIDs (non-chronic, low dose), no additional renal strain will normally occur during or after a trip. For kidney patients or risk groups, the usual warnings regarding NSAIDs apply.

Liver

NSAIDs (especially diclofenac) can rarely cause elevated liver enzymes or hepatotoxicity. Psilocybin itself is not hepatotoxic; psychedelic mushrooms do not damage the liver. There are no cases liver failure has been reported due to psilocybin. (Note: confusion with toxic mushrooms such as Amanita can indeed lead to liver failure, but pure psilocybin mushrooms do not contain amatoxins.) Combined use does not cause additional liver strain, because psilocybin does not concurrently burden CYP enzymes. The greatest liver risk remains NSAID self-use in the presence of pre-existing liver disease or prolonged, high-dose use. In the context of a single trip, liver complaints are highly unlikely.

Heart and blood vessels

NSAIDs can raise blood pressure and slightly increase the risk of cardiovascular disease, particularly diclofenac (even after weeks of use). Psilocybin causes at dosages in studies transit Sympathetic stimulation: average increases of up to ±155/90 mmHg at high doses, and a slight increase in heart rate. These effects are short-lived and normally harmless in healthy individuals. In summary: single use does not lead to chronic hypertension. However, it is true that someone with a serious cardiovascular condition must exercise caution. Theoretically, the blood pressure increase from psilocybin could be slightly amplified by NSAID use, but this is not documented and appears to be small. It has also been investigated that in clinical trials (200+ depression patients), only only a few significant vital changes before and after psilocybin. Conclusion: for healthy adults, the combined effect on the cardiovascular system is limited; However, extra vigilance is required in case of a history of high blood pressure or heart disease.

Influence on the trip experience

There is no indication that NSAIDs alter the psychedelic experience itself. In experimental settings, participants are sometimes given ibuprofen earlier in the day for headache prevention, without this attenuating the visual or cognitive effects. NSAIDs barely cross the blood-brain barrier as an analgesic and do not affect serotonergic activity, so the intensity and nature of the trip remain the same. NSAIDs can reduce physical discomforts (headache, muscle pain, gastrointestinal complaints), which can make the experience calmer. Conversely, it is not known that psilocybin alters the effects of NSAIDs. Anecdotally, users report that mild painkillers “do not spoil the trip.” In summary: concomitant NSAID use will alter the psychedelic effects. not significantly weaken or strengthen, but can reduce negative physical side effects.

NSAIDs after the trip: relieving side effects

Many users experience headaches or muscle pain after a trip. It is common to treat these complaints symptomatically with over-the-counter painkillers. Trials and reviews confirm that ibuprofen or paracetamol can be safely used for psilocybin headaches. In one reported case, a migraine patient took psilocybin (1.2 g magic mushrooms), ibuprofen 400 mg, and paracetamol 1000 mg simultaneously, with excellent pain relief and no adverse effects. In controlled studies as well, participants were explicitly allowed to use OTC analgesics (ibuprofen, aspirin, paracetamol) afterwards for perceived headache. There are no notifications that NSAIDs worsen so-called “trip-ups”. However, it is advisable to drink plenty of water after the trip and not to overdose. Alternatively, paracetamol can be considered in case of stomach or kidney sensitivity, but regular doses of ibuprofen or naproxen are usually sufficient. Conclusion: NSAIDs or paracetamol after the psilocybin trip can cause headaches and muscle pain. safe lighting, without negative interaction.

Available studies and case studies

Case studies and trials specifically examining NSAIDs are rare. A recent systematic review of psilocybin interactions listed only psychotropic drugs (antipsychotics, SSRIs, ketanserine, etc.); NSAIDs were not included. A few case reports are relevant: an adolescent developed acute renal failure after using magic mushrooms (exceptional), while another described complete migraine relief after psilocybin combined with ibuprofen. Prospective studies do show that psilocybin often causes headaches within a few hours, and that participants took ibuprofen/aspirin en masse. Furthermore, clinical trials exist with psilocybin (tens to hundreds of participants) in which elevated blood pressure, heart rate, and headaches have been systematically measured. Not a single publication reported serious side effects from combination with NSAIDs; on the contrary, it is established that NSAIDs may be administered preventively or therapeutically. In general, the current state of research concludes that co-use of NSAIDs not leads to serious complications with psilocybin administration.

Conclusion: Based on available data, ibuprofen, naproxen, or diclofenac in the usual dosage can be considered safe before, during, or after psilocybin use, provided that the standard warnings for NSAIDs (hydration, dose, renal/hepatic status) are observed. No specific contraindications or worsening of the psychedelic trip have been described. However, organ disease (e.g., pre-existing kidney or heart problems) requires caution. In practice, NSAIDs actually prove useful for relieving post-trip symptoms without significantly affecting the trip experience itself.

Sources: Medical literature and pharmacological advice (including clinical trials and case studies).